The Court, upholding the Commission’s argument, held that, to determine whether vitamin preparations or preparations containing minerals should be classified as medicinal products within the meaning of Directive 65/65 on proprietary medicinal products, the national authorities, acting under the control of the court, must work on a case-by-case basis, having regard to the characteristics of those preparations, in particular their composition, their pharmacological properties, the manner in which they are used, the extent of their distribution, their familiarity to consumers and the risks which their use may entail.
Komisjoni argumenti pooldanud Euroopa Kohus leidis, et vitamiinipreparaatide või mineraalaineid sisaldavate preparaatide ravimiteks liigitamise üle otsustamiseks ravimpreparaate käsitleva direktiivi 65/65 tähenduses peavad liikmesriigi asutused kohtu kontrolli all juhtumitega eraldi tegelema, võttes arvesse nende preparaatide kõiki omadusi, eriti nende koostist, farmakoloogilisi omadusi, kasutusviisi, levitamise ulatust, tarbijate teadlikkust nende kohta ja nende kasutamisega kaasnevaid ohte.